TGF-␤1 as an Enhancer of Fas-Mediated Apoptosis of Lung Epithelial Cells
Naoki Hagimoto, 1 P atients with the devastating disorder idiopathic pulmonary fibrosis (IPF) 2 have a median survival of 4 -5 years. Although corticosteroids continue to be the primary treatment, they improve lung function in less than 30% of patients (1) . The etiology of IPF is unknown; however, research over the past 10 -15 years has suggested that fibrosis is initiated by epithelial cell injury. As the disease progresses, the inflammation persists, and there is interstitial fibrosis and a gradual loss of normal lung parenchyma (2, 3) .
TGF-␤1 is important in the fibrotic processes of IPF (4) and bleomycin-induced pulmonary fibrosis in rodents (5) . This cytokine has multiple effects that may exacerbate fibrosis. It is a strong extracellular matrix inducer and is chemotactic for fibroblasts (6) and polymorphonuclear neutrophils (7) . In addition, it can induce apoptosis in gastric carcinoma cells (8) , primary hepatocytes, hepatoma cells (9) , and human lung epithelial cell lines (10) . The mechanism of TGF-␤1-mediated apoptosis most likely varies among cell types, although caspase activation (11, 12) , up-regulation of p21 (13) , and down-regulation of Bcl-x L expression (14) are commonly observed. However, TGF-␤1 induces apoptosis of retinal endothelial cells with decreased expression of p21 (15) . Recently, it was demonstrated that p21 regulates the activation of caspase-3 through procaspase-3-p21 complex formation and protects human hepatoma cells from Fas-mediated apoptosis (16, 17) .
Fas Ag (Fas), a type I membrane receptor protein and a member of the TNFR family (18) , induces apoptosis after engaging with Fas ligand (FasL) (19) . Fas is expressed in various cells and tissues, including the thymus, liver, skin, heart, and lung (20, 21) . Loss of epithelial cells through the Fas-mediated pathway may have an important role in tissue injury and organ dysfunction (20, 22) . Damage to and loss of epithelial cells are also commonly seen in acute lung injury and in chronic fibrosing alveolitis. Furthermore, it is increasingly apparent that Fas ligation can lead to the release of proinflammatory cytokines and can mediate inflammation and tissue injury (23) (24) (25) . We demonstrated that apoptosis and up-regulation of Fas and FasL expression occur in bronchiolar and alveolar epithelial cells and in infiltrating inflammatory cells, respectively, in lung tissue from patients with IPF (26, 27) . We also showed that excessive apoptosis of lung epithelial cells induced by the Fas-FasL pathway is essential for the development of bleomycin-induced pulmonary fibrosis in mice (28) .
Thus, apoptosis of lung epithelial cells by Fas ligation may be involved in the pathogenesis of pulmonary fibrosis, but the role of TGF-␤1 in this process is unclear. Therefore, the first purpose of this study was to investigate whether TGF-␤1 can induce apoptosis of lung epithelial cells and modulates Fas-mediated apoptosis in vitro and in vivo. Second, we investigated whether bronchoalveolar lavage fluid (BALF) from patients with IPF can induce Fasmediated apoptosis of small airway epithelial cells (SAEC) in vitro, and whether TGF-␤1 has some role in this response.
Materials and Methods

Cell culture
Cryopreserved primary human bronchiolar epithelial cells (Clonetics, San Diego, CA) were used between passages 2 and 5. Cells were grown in small airway epithelial cell growth medium (Clonetics) supplemented with hydrocortisone (0.5 g/ml), bovine pituitary extract (30 g/ml), epidermal growth factor (0.5 ng/ml), epinephrine (500 ng/ml), transferrin (10 g/ml), insulin (5 g/ml), retinoic acid (0.1 ng/ml), triiodothyronine (6.5 ng/ml), gentamicin (50 g/ml), amphotericin B (50 ng/ml), and 5% BSA. Cultures were incubated at 37°C in a humidified, 95% air/5% CO 2 atmosphere. After trypsinization, cells were subcultured at densities of 1 ϫ 10 3 cells/ cm 2 . When cells were 50 -60% confluent, the medium was changed to small airway epithelial cell growth medium without hydrocortisone, and the cells were incubated for an additional 24 -48 h, until they reached 70 -80% confluence.
Reagents
Human rTGF-␤1 and mouse anti-human TGF-␤ mAb were obtained from R&D Systems (Minneapolis, MN). Anti-human Fas mAbs for the induction of apoptosis (clone CH-11) and the neutralization of Fas (clone ZB-4) were purchased from MBL (Nagoya, Japan). Benzyloxycarbonyl-Val-AlaAsp (OMe)-fluoromethylketone (Z-VAD.FMK) was purchased from Kamiya (Thousand Oaks, CA). Human rFasL was prepared and purified, as described previously (29) .
Quantification and detection of apoptosis
Cells (10 6 ) were washed in PBS and resuspended in incubation buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 5 mM CaCl 2 ) and Annexin V-FITC (Roche Diagnostics, Indianapolis, IN). After 15 min of incubation at 4°C, fluorescence was analyzed by a Coulter EPICS XL flow cytometer (Coulter, Miami, FL). Apoptotic cells with phosphatidylserine on the outer leaflet of the cell membrane and positively stained by annexin V were determined by setting the analytical region to a brighter fluorescent population that exceeded the upper limit of fluorescence with nonapoptotic specimens. Electron microscopy was performed as previously described (25) .
Caspase activity analysis
Briefly, cells were washed once in PBS and resuspended at 10 8 cells/ml in hypotonic lysis buffer (25 mM/L HEPES, pH 7.5, 5 mM MgCl 2 , 1 mM EGTA, 1 mM PMSF, 1 mg/ml leupeptin, and aprotinin). The lysate was then subjected to four freeze-thaw cycles before centrifugation at 10,000 ϫ g for 10 min, and the supernatants were collected. A total of 20 g extracted proteins was incubated with the fluorescent substrates DEVD-AMC (Ac-Asp-Gul-Val-Asp aminomethyl-coumarin). The fluorescence of cleaved substrates was determined spectrofluorometrically at an excitation wavelength of 360 nm and an emission wavelength of 460 nm.
Western blot analysis
Cells were washed three times with PBS, collected, and lysed in lysis buffer (50 mM Tris, pH 8, 150 mM NaCl, 0.02% sodium azide, 0.1% SDS, 100 g/ml PMSF, 1 g/ml aprotinin, 1% Nonidet P-40, 0.5% sodium deoxycholate) for 10 min at 4°C. Insoluble material was removed by centrifugation at 14,000 rpm for 30 min at 4°C. Frozen lung tissues were homogenized in buffer solution (25 mM HEPES, pH 7.5, 5 mM MgCl 2 , 1 mM EGTA, 1 mM PMSF, 1 g/ml leupeptin, and 1 g/ml aprotinin) using polytron homogenizer. Extracted protein was used for Western blot analysis for cleaved caspase-3. The protein concentration was determined using a Bio-Rad (Melville, NY) protein assay kit. Identical amounts of protein from each lysate (20 g/well) were subjected to 15% SDS-PAGE. Proteins were transferred onto nitrocellulose filters, which were then blocked for 1.5 h using 5% nonfat dried milk in PBS containing 0.1% Tween 20 (PBS-T), washed with PBS-T, and incubated at room temperature for 1 h in the presence of each Ab (mouse monoclonal anti-human p21, rabbit polyclonal anti-human p53, mouse monoclonal anti-human p27, goat polyclonal antihuman Bcl-2, rabbit polyclonal anti-human Bcl-x L , Santa Cruz Biotechnology, Santa Cruz, CA; rabbit polyclonal anti-human X-linked mammalian inhibitor of apoptosis protein (XIAP), R&D Systems; rabbit polyclonal anti-human cleaved caspase-3 Ab, Cell Signaling Technology, Beverly, MA). Filters were washed with PBS-T and incubated with a 1/1000 dilution of sheep anti-mouse IgG, anti-goat IgG, or donkey anti-rabbit IgG, coupled with HRP. The ECL system (Amersham Life Science, Buckinghamshire, U.K.) was used for detection.
Adenoviral vector construction and purification
The recombinant adenoviral vector, AdV-p21, purchased from the RIKEN gene bank (Tsukuba, Japan), was constructed by homologous recombination between sub360 genomic DNA, an adenovirus type 5 derivative with a deletion in the E3 region, and a p21 expression plasmid, pAd-p21, which had the left-hand sequence of adenovirus type 5 genome, but not E1A and E1B. An adenoviral vector encoding lacZ was used for control experiments. The structure of these replication-defective viruses was confirmed by Southern blot analysis. All were propagated in 293 cells, cesium chloride purified, sterilized with a 0.45-m filter, and diluted for storage in 10% glycerol-PBS solution to yield a final concentration of 1-3 ϫ 10 9 viral particles/ml (0.8 -5 ϫ 10 8 PFU/ml). For infection, 5 ϫ 10 5 cells were grown to log phase and infected with adenoviruses at 10 PFU/cell. Fortyeight hours postinfection, the cells were treated with TGF-␤1 for 24 h and analyzed by flow cytometry to quantify apoptosis.
Patient selection
The diagnosis of IPF was made using previously described criteria (2, 30, 31) . All control subjects were healthy volunteers. The diagnosis of hypersensitivity pneumonitis (HP) was based on previously described criteria (32) . BALF were obtained at the time of diagnosis and before steroid therapy. In all patients, current infection with bacteria, mycobacteria, or fungi was excluded by negative cultures of BALF and biopsies.
IPF patients were divided by the clinical indication for steroid therapy at the time of bronchoalveolar lavage (BAL). BALF were obtained before treatment. Patients with acute exacerbation were treated with prednisolone. Acute exacerbation was defined as an increased dyspnea (an increase of Ͼ1 grade in the Hugh-Johns classification system), or a decrease in PaO 2 (Ͼ10 torr in the same condition), accompanied with remarkable exacerbation of the findings on chest x-ray or computed tomography during the prior 2 mo. Predictive vital capacities (mean Ϯ SD) were 57.9 Ϯ 2.8% in IPF with indication of steroid therapy, 67.2 Ϯ 16.9% in IPF without indication of steroid therapy, 92.3 Ϯ 18.4% in HP, and 97.25 Ϯ 8.78% in controls.
BAL procedure and treatment
BAL was performed as previously described (33) . Briefly, BAL was performed using a total of 150 ml sterile physiologic saline solution. The recovered fluid was filtered through a single layer of gauze to remove mucus. Cells in the lavage fluid were counted using a hemocytometer. Differential counts were performed on a total of 100 cells stained with Wright and Giemsa stain. The lavage fluid supernatant was stored at Ϫ70°C until the measurement of soluble FasL (sFasL).
SAEC was incubated in medium supplemented at a 50% concentration with either BALF from patients with IPF, HP, and normal volunteers. The cells were incubated for 24 h at 37°C, 5% CO 2 , then analyzed by flow cytometry to detect apoptosis.
sFasL and TGF-␤1 measurement by ELISA
The BALF sFasL levels were measured with a newly developed ELISA system (34) . In brief, microtiter plates were coated with an anti-human FasL Ab (F918-20-2 Ab). The purified human rFasL produced in pichia pastoris was used as a standard. After an incubation for 2 h at 37°C, the wells were washed with saline containing 0.05% Tween 20. The wells were incubated with the poly peroxidase-labeled anti-human FasL Ab F919-9-18 for 1 h at 37°C, and washed with saline containing 0.05% Tween 20 and distilled water. The wells were incubated with tetramethylbenzidine for 20 min. Peroxidase activity was developed in proportion to the amount of sFasL. The reaction was stopped by adding 1 N H 2 SO 4 . The color generated was determined by measuring the OD at 450 nm in a spectrophotometric microtiter plate reader. The limit of detection (negative control (0 pg/ml) ϩ 2 SD) was 5 pg/ml in BALF. Intra-and interassay coefficient variations were Ͻ2.4 -11.7% and Ͻ8.3-15.7%, respectively. Total TGF-␤1 (after acid activation) in the BALF was analyzed using a sandwich ELISA system (Promega, Madison, WI) with monoclonal capture and polyclonal detection Abs and visualization with tetramethylbenzidine, according to the manufacturer's instructions. We performed all assays in duplicate, and the mean of two data was determined for individual sample.
Treatment of animals
The present study protocol was reviewed and approved by the Committee on Ethics on Animal Experiments, Kyushu University Faculty of Medicine, and the experiments were conducted according to the Guidelines for Animal Experiments of Kyushu University Faculty of Medicine. The 6-wkold ICR mice (30 g) were divided into five groups. The first or second group was treated with agonistic anti-mouse Fas mAb (JO-2; PharMingen, San Diego, CA) dissolved at 10 g/body (n ϭ 20) or 50 g/body (n ϭ 10) in PBS intratracheally. The third group consisted of control mice, treated with isotype-matched control hamster IgG Ab (Organon Teknika, Durham, NC) (n ϭ 20) dissolved at 50 g/body in PBS. The fourth group (n ϭ 20) was treated with human TGF-␤1 dissolved at 500 ng/body in PBS i.v. through the tail vein. The fifth group (n ϭ 20) was treated with 500 ng/ body TGF-␤1 i.v. with 10 g/body anti-Fas Ab intratracheally. TGF-␤1 was injected i.v. at 30 min before anti-Fas Ab instillation intratracheally.
Mice were sacrificed at 6, 12, 18, and 24 h after the treatment. Lung tissues were prepared for the histological examination (H&E staining), the TUNEL method, and Western blot analysis.
Apoptosis analysis in lung tissues
Apoptosis was detected by the TUNEL method using DeadEnd Colorimetric Apoptosis Detection system (Promega). After proteinase digestion and removing of endogenous peroxidase, the sections were incubated in a mixture containing TdT and FITC-labeled dUTP. The sections were then treated with the peroxidase labeled with anti-FITC Ab. The reaction products were developed with 3,3Ј-diaminobenzidine tetrahydrochloride and counterstained with methyl green. Ten fields at ϫ200 were randomly selected, and the number of TUNEL-positive cells was calculated.
Immunohistochemistry
A 5-m paraffin section was adhered to slides pretreated with poly(L-lysine). After the dehydration and the deparaffinization, the tissue sections were autoclaved at 121°C for 5 min in a glass pot filled with distilled water to completely immerse the sections, and washed three times in 0.1 M PBS. Immunohistochemistry was performed using a streptavidin-biotinylated peroxidase technique using a Histofine SAB-PO kit from Nichirei (Tokyo, Japan). The sections were subsequently counterstained with hematoxylin faintly and mounted.
Statistics
Data are expressed as mean Ϯ SD from at least three independent experiments. The data were first analyzed by one-way ANOVA, and statistical significance was determined with multiple comparison methods by Fisher's protected least significant difference.
Results
TGF-␤1 induces apoptosis in bronchiolar epithelial cells (SAEC)
Treatment of SAEC with 25 ng/ml TGF-␤1 for 24 h resulted in 58% cell death with dramatic morphological changes characteristic of apoptosis, such as large vacuoles, cell shrinkage, and cytoplasmic blebbing (Fig. 1, a-f) . TGF-␤1 induced apoptosis in a dosedependent manner (Fig. 1, g and h) . The number of apoptotic cells induced by Fas ligation with anti-human Fas mAb (CH-11) was greater than that induced by TGF-␤1 (Fig. 1i) . The expression of Fas on SAEC was not affected by TGF-␤1 (data not shown).
Involvement of caspase-3 activation in TGF-␤1-mediated apoptosis on SAEC
Because caspase-3 activation is an important element in the apoptotic signaling pathway induced by TGF-␤ (11, 12), we characterized the role of caspase-3 activation in TGF-␤1-induced apoptosis. TGF-␤1 induced caspase-3 activity in a dose-dependent manner (Fig. 2a) , and this was delayed for 12 h compared with that in antiFas Ab-mediated apoptosis (Fig. 2b) . When SAEC were cotreated with the broad-spectrum caspase inhibitor, Z-VAD.FMK, TGF-␤1-induced apoptosis was inhibited in a dose-dependent manner (Fig. 2c) .
TGF-␤1 and CH-11 act synergistically on SAEC
Cells (4% and 12.3%) were induced to apoptosis by a low concentration of TGF-␤1 (0.1 ng/ml) or CH-11 (50 ng/ml), respectively. However, 25.7% of cells were induced with a combination of them (Fig. 3a) . Caspase-3 activity was also markedly increased by the combination compared with TGF-␤1 or CH-11 alone (Fig. 3b) .
TGF-␤1 down-regulates the expression of p21 on SAEC
We also examined the expression of the apoptosis-regulatory proteins, p53, p21, p27, Bcl-2, Bcl-x L , and XIAP. The expression of p21 in SAEC was reduced from 18 to 48 h after TGF-␤1 treatment, independent of p53 expression (Fig. 4a) , and was significantly decreased in apoptotic detached cells compared with untreated or attached living cells (Fig. 4b) . The expression of Bcl-2, Bcl-x L , and XIAP was not affected (Fig. 4a) . In contrast, the low concentration of CH-11 did not affect p21 expression. Z-VAD.FMK had no effect on the decrease of p21 expression after treatment with the low concentration of TGF-␤1 (Fig. 4c) . Therefore, down-regulation of p21 by TGF-␤1 was not caused by caspase cleavage.
Ectopic expression of p21 protects SAEC from TGF-␤1-mediated apoptosis and reduces caspase-3 activity on SAEC
SAEC were infected with an adenoviral vector capable of expressing high levels of p21 (AdV-p21), resulting in a significant elevation of p21 expression relative to that in SAEC infected with an adenoviral vector encoding lacZ (data not shown). AdV-p21-infected cells were well protected from TGF-␤1-induced apoptosis (Fig. 5a) . Simultaneously, caspase-3 activation induced by TGF-␤1 was suppressed by AdV-p21 infection (Fig. 5b) .
rFasL induces apoptotic death in SAEC
Recent results suggest that sFasL is relatively ineffective in inducing apoptosis, and release of sFasL may actually down-regulate the apoptotic activity of the membrane-bound form (35) . However, other investigators demonstrated that bioactive sFasL may have some role in human diseases (33, 36) . Thus, the role of sFasL is controversial. To determine their sensitivity to sFasL, SAEC were exposed to serial dilutions of rFasL ranging from 0.1 to 1000 ng/ml for 24 h. This caused a linear, dose-dependent increase in annexin V binding, ranging from 1 to 1000 ng/ml rFasL. Furthermore, the coincubation with 0.1 ng/ml TGF-␤1 directly enhances the effect of sFasL on SAEC apoptosis (Fig. 6a) .
Effect of BALF from patients with IPF on SAEC apoptosis
We previously demonstrated that sFasL levels in BALF from patients with IPF, especially those who required steroid therapy or those with HP, were elevated compared with those from patients with IPF without indication for therapy or from healthy volunteers (33, 34) . In this study, we measured sFasL concentrations in BALF from 12 patients with IPF (including 5 patients who required steroid therapy), 6 patients with active HP, and 4 normal volunteers. BALF sFasL levels (mean Ϯ SD) were 5.5 Ϯ 3.6 pg/ml in controls. BALF sFasL levels were significantly higher in IPF patients who required steroids (151 Ϯ 66.0 pg/ml, p Ͻ 0.01) and in patients with HP (85.8 Ϯ 41.6 pg/ml, p Ͻ 0.05), but not in IPF patients who did not require therapy, compared with controls. There was a significant difference in BALF sFasL levels between the IPF subgroup with and without steroid therapy ( p Ͻ 0.05) (Fig. 6b) . BALF from patients with IPF (with and without steroid therapy), but not HP, could induce apoptosis of SAEC (Fig. 6c) . To demonstrate the specificity of these effects for sFasL, we incubated SAEC (in medium supplemented at a 50% concentration with BALF from patients with IPF who required steroid therapy) with anti-Fas-neutralizing mAb (ZB-4). Inhibition of Fas ligation with ZB-4 blocked the proapoptotic effect of BALF (Fig. 6d) . To further examine whether TGF-␤1 is involved in BALF sFasL-induced apoptosis, we incubated SAEC in 50% BALF medium with anti-TGF-␤ mAb. Anti-TGF-␤ mAb significantly inhibited apoptosis of SAEC (Fig. 6d) . BALF TGF-␤1 levels (mean Ϯ SD) were 253.6 Ϯ 33.5 pg/ml in controls and 265.0 Ϯ 96.8 pg/ml in HP. BALF TGF-␤1 levels were significantly higher in both IPF patients who required steroid therapy (493.7 Ϯ 105.0 pg/ml, p Ͻ 0.01) and IPF patients who did not require steroid therapy (451.5 Ϯ 58.5 pg/ml, p Ͻ 0.01) compared with that in BALF from control or HP group. There was no significant difference in BALF TGF-␤1 levels between the IPF subgroup with and without steroid therapy (Fig. 6e) . Finally, coincubation with 0.1 ng/ml TGF-␤1 and HP BALF created proapoptotic effects comparable with the IPF BALF (Fig. 6f) .
TGF-␤1 enhanced Fas-mediated epithelial cell apoptosis and lung injury via caspase-3 activation in vivo
To confirm the direct link of TGF-␤1 to apoptosis of lung epithelium in vivo, we used Fas-mediated lung injury model in mice. Nine of ten mice treated with 50 g/body agonistic anti-Fas Ab were dead within 24 h. In these mice, other Fas-susceptible organs, such as liver, kidney, and heart, were almost intact pathologically (data not shown). They were very tachypneic and exhausted. Therefore, it is likely that acute lung injury was the main cause of death. Although none of mice treated with i.v. injection of 500 ng TGF-␤1 or intratracheal instillation of 10 g anti-Fas Ab was dead, half of mice treated with the combination of these two treatments were dead (Fig. 7) . The i.v. injection of 500 ng/body TGF-␤1 or intratracheal injection of 10 g/body anti-Fas Ab alone induced mild inflammation (Fig. 8, a and b) . However, the treatment of anti-Fas Ab with TGF-␤1 induced severe lung inflammation and apoptosis of epithelial cells (Fig. 8, c and d) . The number of TUNEL-positive cells was significantly increased compared with controls at 12-24 h after the treatment of anti-Fas Ab with TGF-␤1. However, the TGF-␤1 or anti-Fas Ab treatment alone did not significantly increase the number of apoptotic cells, except at 18 h after the TGF-␤1 treatment (Fig. 9) . The results of Western blot analysis show that the caspase-3 activation was significantly increased predominantly at 12-18 h after the treatment of anti-Fas Ab with TGF-␤1 compared with that after the treatment of TGF-␤1 or anti-Fas Ab alone (Fig. 10a) . The results of immunohistochemistry showed that the expression of cleaved casapase-3 was predominantly detected in alveolar epithelial cells (Fig. 10b) . 
Discussion
Lung epithelial cells are recognized as the primary site of lung damage in pulmonary fibrosis. As we previously reported, apoptosis of lung epithelial cells by Fas ligation may be involved in lung injury and fibrosis (25) (26) (27) (28) . There are multiple effects of TGF-␤1 that can explain amplification of pulmonary fibrosis. TGF-␤1 is prominently expressed in macrophages and epithelial cells and found to be associated with the extracellular matrix using immunohistochemistry in IPF (37) . In lungs with early lesions of IPF and only inflammatory changes, TGF-␤1 is present in alveolar macrophages, but not present in epithelial cells (37) . In bleomycininduced pulmonary fibrosis model in rat, TGF-␤1 is expressed in alveolar macrophages at acute phase of inflammatory cell infiltration, and in epithelial cells at later phase of pulmonary fibrosis (38) . It seems that the expression of TGF-␤ may associate with inflammation at acute phase, and with tissue remodeling at late phase. Therefore, the significance of TGF-␤1 in IPF and animal models of pulmonary fibrosis is well known; however, it is unclear FIGURE 6. a, The effect of serial dilutions of sFasL on SAEC with or without 0.1 ng/ml TGF-␤1. Results are shown as mean Ϯ SD of three experiments. b, BALF sFasL levels in patients with IPF with (IPF ϩ S) or without (IPF Ϫ S) indication of steroid therapy, HP, and controls. The mean is indicated by the horizontal bar; each F represents one individual. c, Effect of BALF from patients with IPF, HP, and controls on SAEC. SAEC was incubated in medium supplemented at a 50% concentration with either BALF from patients with IPF, HP, and normal volunteers. The cells were incubated for 24 h at 37°C, 5% CO 2 , then analyzed by flow cytometry to detect apoptosis. d, Inhibition of BALF-induced apoptosis of SAEC with anti-Fas Ab and anti-TGF-␤ Ab. SAEC was incubated in BALF medium from patients with IPF (n ϭ 5) with anti-Fas Ab (neutralization of Fas; clone ZB-4) (1 g/ml) or mouse anti-human TGF-␤ mAb (5 g/ml) for 24 h, then analyzed by flow cytometry to detect apoptosis. e, BALF TGF-␤1 levels in patients with IPF with (IPF ϩ S) or without (IPF Ϫ S) indication of steroid therapy, HP, and controls. The mean is indicated by the horizontal bar; each F represents one individual. f, The enhanced effect of low concentration of TGF-␤1 (0.1 ng/ml) on HP BALF-induced apoptosis on SAEC. SAEC was incubated in BALF medium from patients with HP (n ϭ 4) with the concentration of 0.1 ng/ml TGF-␤1 for 24 h, then analyzed by flow cytometry to detect apoptosis. ‫,ءء‬ p Ͻ 0.01; ‫,ء‬ p Ͻ 0.05.
whether TGF-␤1 participates in the epithelial cell injury and apoptosis.
We performed this study to investigate the effect of TGF-␤1 on Fas-mediated apoptosis in lung epithelial cells. Our data show that TGF-␤1 can induce apoptosis of SAEC through the caspase-3 activation and the down-regulation of the p21 expression. In addition, a low concentration of TGF-␤1 that could not induce apoptosis alone enhanced Fas-mediated apoptosis of SAEC. Concomitant with our studies, others reported that this process involved the activation of caspase-3 (11, 12) or the down-regulation of Bcl-x L (14) . However, we found that the caspase-3 activation by TGF-␤1 leads to SAEC apoptosis without the down-regulation of Bcl-x L expression. We found the p53-independent down-regulation of p21 expression by TGF-␤1, even at the low concentration. Detached apoptotic cells exhibited significantly reduced levels of p21 expression, whereas attached living cells exhibited elevated levels. Thus, for SAEC, induction of p21 appears to be correlated with resistance to TGF-␤1-mediated apoptosis. It is also possible that in the presence of TGF-␤1, p21 protects SAEC from apoptosis. This hypothesis appears to be valid for myocyte differentiation in low serum (39) , and similar observations have been reported in neuroblastoma (40) or colorectal carcinoma cell lines (41) . To confirm this protective effect, we infected SAEC with AdV-p21. Ectopic expression of p21 protected SAEC from TGF-␤1-mediated apoptosis and reduced caspase-3 activity. Interestingly, some investigators have demonstrated that activation of caspase-3 is regulated by p21, and procaspase-3-p21 complex formation is an essential system for cell survival (42, 43) . Therefore, the down-regulation of p21 by TGF-␤1 may enhance Fas-mediated apoptosis through caspase-3 activation. Since the down-regulation of p21 expression by the low concentration of TGF-␤1 was not affected by a caspase inhibitor, another regulatory system, such as the ubiquitin proteasome system (44), may be involved in the down-regulation of p21.
We previously demonstrated that the concentrations of sFasL in BALF from patients with IPF and HP were significantly higher than those in BALF from normal volunteers (33, 34) . In addition, sFasL can be released in BALF from patients with acute respiratory distress syndrome as a biologically active molecule that can induce apoptosis of the pulmonary epithelium (45) . In this study, we demonstrated that BALF from patients with IPF, but not HP, could induce apoptosis of SAEC, despite the fact that BALF from both IPF and HP contained similar concentrations of sFasL. AntiFas-neutralizing Ab could significantly inhibit SAEC apoptosis induced by BALF from patients with IPF. However, much higher concentrations of rFasL were required for the induction of apoptosis in vitro (Fig. 6a) . BALF TGF-␤1 levels were significantly higher in both steroid-indicated and not indicated IPF patients compared with that in BALF from HP patients. Anti-TGF-␤-neutralizing Ab inhibited apoptosis of SAEC induced by BALF administration. Furthermore, adding TGF-␤1 to the HP BALF created proapoptotic effects comparable with the IPF BALF. Thus, TGF-␤1 may act synergistically as a cofactor for the development of a full apoptotic response to sFasL in BALF from patients with IPF. This may be one explanation for the difference in prognosis between IPF and HP. Patients with HP usually improve spontaneously by isolating patients from Ag. As other investigators demonstrated, fibroblasts are refractory to Fas-mediated apoptosis, and TGF-␤1 can abrogate this resistance (46) . These opposing responses to Fas ligation or TGF-␤1 between epithelial cells and fibroblasts may be one of a key mechanism of pulmonary fibrosis. Furthermore, it was demonstrated that the increased production of TGF-␤1 could not be suppressed by the high-dose corticosteroids treatment in bleomycin-induced pulmonary fibrosis in rat (47) . This result may be an explanation for the ineffectiveness of corticosteroids treatment in patients with IPF.
Finally, to confirm the direct link of TGF-␤1 to apoptotic effects in a physiologically relevant system in vivo, we designed the Fasmediated lung injury model of mice. Matute-Bello et al. (48) demonstrated that lung epithelial cell apoptosis and acute inflammation were caused by intranasal instillation of agonistic anti-Fas Ab in mice. We also previously demonstrated that repeated inhalation of anti-Fas Ab induced lung injury and fibrosis in mice (49) . The intratracheal instillation of 50 g anti-Fas Ab killed 90% of mice within 24 h. Because the intratracheal instillation of anti-Fas Ab did not affect other Fas-susceptible organs, we presumed that the respiratory failure induced by Fas-mediated lung epithelial cell apoptosis and inflammation was the cause of death. In this model, TGF-␤1 enhanced lung epithelial cell apoptosis and inflammation induced by low dose of anti-Fas Ab, and increased the mortality of mice. Western blot analysis using extracts from lung homogenates demonstrated that the cleaved caspase-3 was significantly increased from 12 to 18 h after the treatment of anti-Fas Ab with TGF-␤1. Thus, TGF-␤1 augments Fas-mediated apoptosis on lung epithelium via the caspase-3 activation in vivo. As seen in the vitro system, TGF-␤1 alone also induced the caspase-3 activation and apoptosis on lung epithelial cells. It is possible that TGF-␤1 may be a primary factor, which induces lung injury in the course of pulmonary fibrosis.
We conclude that TGF-␤1 is a potent inducer of apoptosis through the caspase-3 activation and the down-regulation of p21 and is also an enhancer of Fas-mediated apoptosis of lung epithelial cells. This novel function of TGF-␤1 in apoptosis of lung epithelial cells should be considered in the treatment of pulmonary fibrosis, and could be a new treatment strategy. 
